Market Overview

Perrigo Announces FDA Final Approval and Launch of Store Brand OTC Lansoprazole 15mg Capsules

Share:
Related PRGO
The Market In 5 Minutes: Stocks Trading Higher As Earnings Season Quiets Down
Benzinga's M&A Chatter for Tuesday August 23, 2016

Perrigo Company (Nasdaq: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application (ANDA) for Lansoprazole capsules (15 mg). Shipments of product to customers have already begun.

This new product for the U.S. store brand market is bioequivalent to Novartis' Prevacid® 24HR capsules (15 mg) and is indicated for the treatment of frequent heartburn, which occurs two or more days in a week. Sales for Prevacid OTC were approximately $220 million.

Posted-In: News FDA

 

Related Articles (PRGO)

View Comments and Join the Discussion!